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Abstract
Background: IdeS, a proteinase from Streptococcus pyogenes, cleaves immunoglobulin (Ig)G antibodies with a unique
degree of specificity. Pathogenic IgG antibodies constitute an important clinical problem contributing to the pathogenesis
of a number of autoimmune conditions and acute transplant rejection. To be able to effectively remove such antibodies is
therefore an important clinical challenge.
Methodology/Principal Findings: IdeS was found to specifically and efficiently cleave IgG in human blood in vitro (20 mgo f
IdeS caused a complete degradation of IgG in one ml of human whole blood in 15 minutes) and to clear IgG from the blood
stream of rabbits in vivo (no IgG was detected six hours following an intravenous injection of 5 mg of IdeS) without any side
effects. In a mouse model of immune thrombocytopenic purpura (ITP), polyclonal IgG antibodies against platelet surface
antigens were used to induce a lethal disease. These profoundly thrombocytopenic animals were treated and cured by a
single injection of IdeS.
Conclusions/Significance: Novel information is provided concerning the IgG-cleaving activity of IdeS in vitro and in vivo.
The highly specific and rapid elimination of IgG in vivo, the dramatic effect in a mouse model of ITP, and the lack of side
effects in the treated animals, indicate that IdeS could also be used to treat IgG-driven diseases in humans.
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Introduction
Antibodies play an important role in the defence against
invading microorganisms. Among the five classes of antibodies,
immunoglobulin (Ig)G is the quantitatively dominating class, and
apart from albumin the most abundant protein in human blood
(7–16 mg/ml blood plasma). Besides its protective role, IgG is also
involved in disease. It is estimated that autoimmune diseases affect
about five percent of people [1], and in many of these conditions
(rheumatoid arthritis, systemic lupus, myasthenia gravis, immune
(or idiopathic) thrombocytopenic purpura (ITP), Goodpasture’s
syndrome, etc) IgG autoantibodies reacting with human molecules
contribute to the pathogenesis. They also cause acute transplant
rejection, bind and inactivate life-saving hemophilia factors,
whereas overproduction of IgG in patients with multiple myeloma
is associated with a hyperviscosity syndrome. In these conditions
removal of pathogenic IgG antibodies from the blood circulation
represents a logical therapeutic strategy, and extracorporeal
immunoadsorption where patient plasma is passed over columns
that bind IgG, has indeed proven to be beneficial in several
autoimmune conditions [2–7]
Streptococcus pyogenes, a significant bacterial pathogen, secretes two
enzymes showing remarkable specificity for IgG; EndoS and IdeS.
EndoS (Endoglycosidase in Streptococcus pyogenes) efficiently and
specifically hydrolyzes the functionally important N-linked glycan
of IgG [8], and treatment with EndoS abrogates the pathogenic
activity of IgG in mouse models of autoimmune disease [9,10].
IdeS (Immunoglobulin G-degrading enzyme of Streptococcus
pyogenes) is a cysteine proteinase which cleaves IgG with a unique
degree of specificity in the hinge region [11,12], and in a recent
study the enzyme was found to block the development of IgG-
induced arthritis in a mouse model of disease [13]. In the present
work we further investigate the potential of IdeS for the treatment
of conditions involving pathogenic IgG antibodies. The results
demonstrate that the enzyme in vitro efficiently cleaves IgG in
human whole blood, removes IgG from the blood circulation of
rabbits without any side effects, and cures mice from lethal IgG-
induced thrombocytopenia.
Results and Discussion
IdeS [11,12], also called Mac-1 [14], is a proteolytic enzyme
produced by the bacterial pathogen Streptococcus pyogenes, which
cleaves IgG with a unique degree of specificity [11,15]. Before
IdeS can cleave IgG in the heavy chain (see Fig. 1A) the enzyme
has to bind to the Fc region of the antibody, and the remarkable
specificity of IdeS lies in this protein-protein interaction [15]. The
IgG molecule is composed of two heavy and two light chains
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(throughout this study a 61 kDa IdeS fusion protein with GST was
used) cleaves IgG in the heavy chains (Fig. 1A), which generates
one F(ab9)2 and two monomeric Fc fragments. When these
fragments are separated by SDS-PAGE under reducing conditions
(to break the disulfide bonds), the heavy chains give rise to bands
of 25 (the Fc monomers) and 31 kDa (the remaining part of the
heavy chains), and the light chains dissociate from the (Fab9)2
fragments. Since the molecular mass of the light chains is also
25 kDa, SDS-PAGE of IgG completely cleaved by IdeS will
generate two bands of 25 and 31 kDa, respectively, whereas SDS-
PAGE of uncleaved IgG under reducing conditions produces two
bands corresponding to intact heavy (56 kDa) and light (25 kDa)
chains (Fig. 1B, lanes 1 and 2).
To investigate the IgG-cleaving activity of IdeS in blood, whole
human blood was incubated with IdeS and a complete
degradation of IgG was obtained (Fig. 1B, lanes 3 and 4). Most
individuals have been infected with S. pyogenes bacteria and
antibodies against streptococcal proteins, including IdeS, are very
common in the human population [16]. It has been reported that
convalescent-phase sera from patients with S. pyogenes infections in
some cases partially inhibit the activity of IdeS [17]. In that study,
the concentration of IdeS was approximately a thousand fold
lower as compared to the concentration used here. It should also
be mentioned that streptokinase, a plasminogen activator and like
IdeS a protein of S. pyogenes, has been used therapeutically as a
thrombolytic agent for decades. In these patients antibodies
against streptokinase are often present, but seldom cause problems
unless the patients are treated repeatedly. In addition, it could be
that IdeS by cleaving IgG antibodies, including IgG directed
against itself, is less sensitive to neutralizing IgG antibodies in
comparison to streptokinase and other protein antigens. However,
neutralizing antibodies against IdeS are of course a potential
problem, and we therefore tested the IgG titers against IdeS in
nineteen healthy individuals. As expected, all had anti-IdeS IgG
antibodies (Fig. 2A), but the cleavage of IgG by IdeS was not
affected even in the sera with the highest titers against IdeS
(Fig. 2B). The results show that these antibodies do not inactivate
the IgG-cleaving activity of IdeS when used at a concentration
(20 mg IdeS/ml plasma) that completely cleaves IgG in human
blood (Fig. 1B, lane 4). This does of course not exclude the
possibility that repeated injections of IdeS in humans, as is the case
with streptokinase, may cause problems in some patients due to
neutralizing antibodies or allergic reactions.
To test IdeS toxicity and IgG cleavage in vivo under conditions
resembling a clinical situation, we needed to find an animal species
in which all IgG subclasses, as in humans [11], are cleaved by
IdeS. Only partial cleavage was obtained with polyclonal mouse
Figure 1. IdeS cleaves IgG in human blood. (A) Structure of IgG. The IdeS cleavage sites are indicated. (B) The following samples were separated
by SDS-PAGE. Lane 1: Five mg of human polyclonal IgG in 10 ml PBS. Lane 2: Five mg of human polyclonal IgG and 1 mg of IdeS in 10 ml PBS (IgG and
IdeS were preincubated for three hours at 37uC before SDS-PAGE). Lane 3: Ten ml of plasma from human blood diluted 1:50 in PBS Lane 4: One
hundred ml of human blood was preincubated with 1 mg of IdeS for three hours at 37uC. The plasma from this sample (containing approximately
20 mg/ml) was diluted 1:50 in PBS, and 10 ml of this material was separated in lane 4. The asterisk indicates the IgG heavy chain.
doi:10.1371/journal.pone.0001692.g001
Figure 2. IgG antibodies against IdeS in human sera do not interfere with the enzymatic activity. (A) Antibody titers against IdeS in
serum samples from nineteen healthy donors (D1–D19). (B) SDS-PAGE analysis of serum samples untreated (2) or preincubated with IdeS (20 mg/ml
serum) for three hours at 37uC( +).
doi:10.1371/journal.pone.0001692.g002
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found to be completely degraded (Fig. 3A). The total degradation
of both human and rabbit IgG, and the fact that multiple serum
samples are easier to obtain from rabbits than from mice, made us
choose rabbits for the initial in vivo experiments. Before IdeS was
injected into rabbits, we titrated the IgG-cleaving activity of the
enzyme in rabbit and human whole blood in vitro. A complete
cleavage of IgG in 1 ml rabbit blood in 15 minutes at 37uC, was
found to require 5 mg of IdeS, which corresponds to 1.6 mg IdeS/
mg rabbit IgG. In human blood 20 mg/ml (3.9 mg IdeS/mg IgG)
was required for total IgG degradation, i.e. IdeS cleaves rabbit IgG
more effectively than human IgG.
A first rabbit was injected intravenously (i.v.) with 5 mg
(corresponds to approx. 10 mg/ml blood) of IdeS on day 0 and
day 40. Blood samples were drawn at different time points and
analyzed for IgG and IdeS content (Fig. 3B, left panel). The effect
of IdeS was rapid and efficient; within six hours intact IgG could
no longer be detected in the blood stream (Fig. 3B). The clearance
of the F(ab
1)2 fragments generated by the IdeS treatment, was
analyzed by following the presence of the 31 kDa heavy chain
fragment (see Fig. 1 and Fig. 3A) in the rabbit blood samples by
SDS-PAGE (data not shown). This fragment, and thereby the
F(ab
1)2 fragments, was cleared from the circulation within two
days. After 4–5 days IgG started to reappear and was back to
normal levels on day 10. IdeS was not detectable after day three
(Fig. 3B, left panel), and since the GST-IdeS fusion protein used
here is 61 kDa (Fig. 1B), the protein is most probably cleared via
the kidneys analogous to other proteins in plasma with a molecular
mass below that of albumin (69 kDa). The IdeS injection was
repeated on day 40, and the same pattern was seen (Fig. 3B, right
panel). The cleavage and clearance of IgG, and the clearance of
IdeS, were similar in five additional rabbits, and no apparent side
effects were observed in any of the IdeS-treated rabbits. Two of
the rabbits, each injected i.v. on six different occasions with 5 mg
of IdeS during a period of eight months, were sacrificed. Histo-
pathological analysis of the organs revealed normal heart, lung,
liver, spleen, and kidney tissue.
The very rapid and efficient cleavage and removal of IgG from
the circulating blood of rabbits by IdeS, suggest that the enzyme
could be used for the treatment of acute autoimmune conditions
such as acute transplant rejection, Goodpasture’s syndrome, severe
relapses of systemic lupus, and immune thrombocytopenic
purpura (ITP). In patients with ITP, polyclonal IgG autoantibod-
ies react with different glycoproteins at the platelet surface [18].
IgG bound to the platelet surface will expose their Fc regions and
bind to Fcc receptors displayed by macrophages. As a result IgG-
coated platelets are rapidly phagocytosed by macrophages
(predominantly in the spleen and the liver), and the lifespan of
platelets that enter the blood where such autoantibodies are
present, is only a few hours compared to a normal life span of ten
days. This rapid elimination exceeds the rate of production of
platelets in the bone marrow, and leads to an acute or chronic
thrombocytopenia and associated bleeding disorder. A mouse
model which closely mimics ITP is available, where rabbits are
immunized with mouse platelets and polyclonal IgG purified from
the sera of these rabbits, are injected into mice [19]. When the
antibodies bind to antigens on the platelet surface, the mice rapidly
develop thrombocytopenia and petechiael haemorrhaging, and
they eventually succumb to massive internal bleeding. To test the
effect of IdeS in an animal model of an acute autoimmune
condition, this mouse model was very relevant. The fact that
polyclonal rabbit IgG is used to induce the disease is also a great
advantage, since IdeS has the potential capacity to cleave all the
administered rabbit IgG antibodies. Thus, polyclonal IgG was
purified from a rabbit antiserum raised against mouse platelets,
and the purified rabbit anti-mouse platelet IgG antibodies were
injected intraperitoneally (i.p.) into mice. As previously reported
the antibodies rapidly induced a severe thrombocytopenia in the
animals [19,20]. Following a pilot experiment where 1.0 mg of the
purified rabbit IgG was found to cause a lethal thrombocytopenia
in the treated mice within 24 hours, fourteen mice were each
injected i.p. with this dose of IgG. Thirty minutes later seven of the
mice were injected, also i.p., with 0.5 mg IdeS diluted in PBS
buffer, and seven with buffer alone. An IgG control was not
necessary since previous studies using this model have shown that
administration of polyclonal IgG purified from non-immunized or
PBS-immunized rabbits, does not affect platelet numbers or the
survival of mice [19,20]. In the PBS group all animals died from
severe bleeding within 24 hours. In contrast, the IdeS treated mice
showed no signs of disease and they were sacrificed after two weeks
of observation. To investigate the effect of IdeS when the enzyme
is administered through another route than the IgG antibodies,
Figure 3. Invivo cleavage and removal of IgG from the blood circulation of rabbits injected with IdeS. (A) SDS-PAGE of rabbit polyclonal
IgG (5 mgi n1 0ml PBS) alone (lane 1), or preincubated with IdeS (5 mg IgG and 1 mg IdeS in 10 ml PBS) for three hours at 37uC (lane 2). Bands
corresponding to IdeS (61 kDa), IgG heavy chains (Hc, 56 kDa), IdeS-generated Hc fragments (31 kDa) and IgG light chains ( Lc, 25 kDa), are indicated.
(B) Levels of IgG (grey bars) and IdeS (e) in serum samples from a rabbit injected i.v. with IdeS (5 mg diluted in 2.5 ml PBS). IgG was determined by
ELISA and IdeS by Western blotting and chemoluminescence in a Chemidoc XRS Imaging system. Samples were analyzed three times and mean
values6SD are indicated.
doi:10.1371/journal.pone.0001692.g003
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thirty minutes, six were treated with 0.5 mg IdeS in PBS, but this
time the enzyme was injected i.v.. The remaining six mice were
given PBS alone, also i.v. Again the buffer treated animals were all
dead within 24 hours, whereas the IdeS treated animals remained
healthy and unaffected until sacrificed two weeks later. The results,
summarized in Fig. 4A, show that thirteen mice treated i.p. or i.v.
with IdeS, all survive a lethal dose of IgG antibodies. This effect is
explained by the data shown in Fig. 4B and C. Blood samples from
the mice injected i.v. with IdeS or PBS alone, were analyzed by
flow cytometry. The platelets in the samples were also counted
manually. In the IdeS treated mice, the number of platelets was
reduced by approximately forty percent at six hours, but was back
to normal levels after 2–3 days. The initial drop in platelet
numbers also in IdeS treated mice, demonstrates that the IgG
antibodies rapidly bind to the platelets and induce the lethal
condition. However, although the disease process has already
started it is counteracted when IdeS appears in the circulation. In
contrast, no platelets could be detected in the buffer treated
animals after six hours, and they died 3–18 hours later. In a final
set of experiments, we investigated whether IdeS is effective also
when the enzyme is administered later during the time course of
the thrombocytopenia. Three mice where injected with the rabbit
antibodies, and the number of platelets were counted in order to
determine the time point when profound thrombocytopenia
occurs. After three hours no platelets were present in the blood
of two of the mice, and in the third mouse the number was
reduced by more than 90% (Fig. 5A). Subsequently, ten additional
mice were injected i.p. with the lethal dose of IgG antibodies
(1 mg/mouse). At three hours, nine of the animals had no
circulating platelets and one had less than 15% of its original
number. At this point the mice were divided into two groups of
five animals each. One group was treated i.v. with IdeS (none of
the animals in this group had any circulating platelets), and the
mice of the other group received PBS alone. In this latter group
four animals had no circulating platelets and one had less than
15% of its original level. The effect was dramatic; PBS treated
mice remained thrombocytopenic and died 15–27 hours later,
whereas the IdeS treated mice all recovered their platelet levels
and survived (Fig. 5B). These experiments show that IdeS is
capable of rescuing the animals also when they have developed a
profound and a otherwise lethal thrombocytopenia.
The results of this study demonstrate that IdeS efficiently
degrades IgG in human whole blood in vitro, cleaves and clears IgG
Figure 4. IdeS cures mice from lethal IgG-induced thrombocytopenia. (A) Fourteen BALB/C mice were injected i.p. with a lethal dose of
purified polyclonal rabbit IgG antibodies (1 mg IgG/ mouse, diluted in 0.25 ml PBS) raised against mouse platelets. Thirty minutes later, seven mice
were treated i.p. with 0.5 mg IdeS in 0.25 ml PBS and seven with 0.25 ml PBS alone. In another experiment, twelve Balb/c mice were injected i.p. with
the lethal dose of IgG. After thirty minutes, six mice were given 0.5 mg IdeS in 0.25 ml PBS, and six were given 0.25 ml PBS alone. In this case, the
injections were given i.v. The thirteen IdeS treated mice (#) all survived, whereas the thirteen PBS treated mice (&) all died within 24 hours. (B)
Blood samples from the twelve mice injected with the lethal dose of purified rabbit IgG and treated i.v. with IdeS or PBS alone (six mice in each
group), were analyzed using flow cytometry of the platelet population. Samples from two representative animals, one injected with IdeS and one
with PBS, are shown. (C) The number of platelets in the blood samples from the twelve animals treated i.v. was counted manually; six treated with
IdeS (#) and six with PBS (&). Error bars indicate 6SEM.
doi:10.1371/journal.pone.0001692.g004
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lethal IgG-induced thrombocytopenia. Before IdeS can be used in
patients, regulatory issues have to be addressed, but the present
work indicated that the enzyme has a clinical potential. The
unique and astonishing specificity of IdeS further underlined by
this work, means that the other classes of antibodies are not
cleaved [11], which reduces the risk of creating a serious Ig
deficiency (none of the rabbits treated with IdeS showed any signs
of infection). Cleaved and removed IgG antibodies could also be
replaced as soon as IdeS has been cleared from the circulation.
Such replacement together with an immunosuppressive regimen,
may block or postpone the reappearance of pathogenic IgG
antibodies. On the other hand, if the clinical condition should
require a longer period of IgG deprivation, the half life of IdeS in
the blood stream can be prolonged by producing a larger IdeS
fusion protein. Finally, the lack of side effects and the efficient and
reproducible activity when injected in vivo, also indicate a
therapeutic potential of IdeS.
Materials and Methods
Recombinant expression and purification of IdeS
The expression of recombinant GST-IdeS in Escherichia coli has
previously been described [11]. The fusion protein was purified on
Glutathione Sepharose 4 Fast Flow (Amersham Biosciences)
according to standard protocols, dialyzed against phosphate buffer
saline (PBS), and sterile filtered through a 0.22 mm Millex-GP
filter unit (Millipore Inc.). The protein concentration was
determined using Advanced protein assay reagent (Cytoskeleton).
SDS-PAGE and analysis of IdeS activity
Proteins analyzed by SDS-PAGE were separated under
reducing conditions on Nu-PAGE 4–12% Bis-Tris gels (Invitro-
gen) and stained with Coomassie Blue. Purified human IgG was
purchased from European Institute of Science, purified rabbit IgG
was purchased from Dakopatts, and blood samples were collected
from healthy human donors. All activity assays with GST-IdeS
(cleavage of IgG) were performed for 3 h at 37uC, and serum
samples were diluted 50x in PBS prior to analysis by SDS-PAGE.
Injections of IdeS into rabbits
Six Swedish loop rabbits (weighing approximately 5.0 kg) were
injected i.v. with 5 mg GST-IdeS at day 0. Serum samples were
collected from the ear vein at different time points and kept at
220uC until being analyzed for IgG and IdeS content. The
procedure was repeated a second time at day 6 or at day 40 in all
rabbits. To investigate possible toxic side effects of IdeS, all six
rabbits were further injected up to six times with 5 mg GST-IdeS
and visually monitored for signs of disease. After six intravenous
injections, heart, lung, liver, spleen, and kidney tissue from two of
the rabbits was subjected to histo-pathological analysis.
IgG quantification in rabbit serum
To measure IgG clearance in vivo, rabbit serum samples were
analyzed by SDS-PAGE and ELISA. In brief, Microtiter plates
(Maxisorb, NUNC) were coated over night with rabbit serum
samples diluted 5610
4 times in coating buffer (0.05 M NaHCO3,
pH 9.6). Plates were washed in PBST (0.05% Tween in PBS) and
blocked with 2% bovine serum albumin (Sigma). IgG was detected
using peroxidase-conjugated protein G (1:3000, Bio-Rad) and the
total amount of IgG in eachsample wascalculated bycomparing the
optical densites at 415 nm with a sequential dilution of rabbit IgG of
known concentration. All analyses were performed in triplicates and
the mean value 6SD for each sample was calculated.
Determination of IdeS in rabbit serum
The circulation time of GST-IdeS inrabbit blood was determined
byincubating200 mlofrabbitserumsampleswith40 mlGl ut at hi o ne
Sepharose 4B (Amersham Biosciences) for 60 minutes at 4uC.
Following centrifugation, the pellets containing GST-IdeS and
Glutathione Sepharose beads were boiled in 100 mls a m p l eb u f f e r
Figure 5. IdeS treatment of thrombocytopenia is effective also
when initiated at low platelet levels. (A) Blood samples were taken
at regular time intervals from three mice injected i.p. with a lethal dose
of rabbit anti-mouse platelet IgG antibodies (1 mg IgG/mouse), and the
number of platelets was determined by manual counting. (B) An
additional ten mice were injected with the lethal dose of IgG. At three
hours, five mice were treated i.v. with IdeS (0.5 mg in 0.25 ml PBS/
mouse), while the other five received PBS alone (0.25 ml i.v/mouse). The
PBS treated animals remained thrombocytopenic and died within 18–
30 hours of IgG administration, whereas the IdeS treated animals all
recovered their platelet levels and survived. These animals were
sacrificed on day 14.
doi:10.1371/journal.pone.0001692.g005
Clearance of Pathogenic IgG
PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1692and separated by SDS-PAGE. Samples were transferred to
Immobilon-P transfer membranes (Millipore Inc.), and the extracted
GST-IdeS was detected by rabbit serum containing specific anti-
IdeS antibodies (1:1000) as primary antibody followed by peroxi-
dase-coupled Protein G (1:3000, Bio-Rad). Incubations, performed
for 1 h at 22uC, were followed by a washing step in PBST. GST-
IdeS was visualized by chemiluminescence in a Chemidoc XRS
imaging system, and the total amount of GST-IdeS present in the
samples was calculated using Quantity One 1-D Analysis software,
version 4.6 (Bio-Rad). The sensitivity of the assay is below 0.1 mg/ml
serum. All analyses were performed in triplicates and the mean
value6SD for each sample was calculated.
Histo-pathological analysis
Rabbit organs were fixed in 4% paraformaldehyde (in PBS,
pH 7.4) and processed for routine histo-pathological evaluation.
IgG-induced thrombocytopenia in mice
Rabbit antiserum raised against mouse platelets was purchased
from Intercell Technologies. IgG antibodies isolated from this
serum were affinity purified on a Protein G column (Amersham
Biosciences). Briefly, the column was prepared by washing with
PBS and the rabbit antiserum was loaded onto the column. IgG
bound to the column was eluted using acid glycine (0.1 M glycine,
pH 2.0) and collected into neutralization buffer (1 M unbuffered
Tris). IgG-containing fractions were pooled and the protein
concentration was determined with SDS-PAGE and Advanced
protein assay reagent (Cytoskeleton).
Female BALB/c mice (weighing approximately 20 g) were
housed under standard conditions of light and temperature and
were fed standard laboratory chow and water ad libitum. Rabbit
anti-mouse platelet IgG was administered to the animals by i.p.
injection. In pilot experiments 1.0 mg of purified IgG induced a
lethal thrombocytopenia within 24 hours. Thirty-six mice were
each injected i.p. with this dose of IgG (in 0.25 ml PBS). Thirty
minutes or three hours later, the mice were treated with either an
i.p. or an i.v injection of 0.5 mg IdeS diluted in 0.25 ml PBS, or
with PBS alone. The animals were monitored for signs and
symptoms of disease, and the survival time was recorded.
Blood sampling from thrombocytopenic mice and
platelet analyses
Immediately prior to the injection of rabbit anti-mouse IgG and
at regular intervals during the course of the disease, blood samples
were taken from the mice. The tail vein was pre-warmed and 5 ml
of whole blood was collected into a tube containing 45 ml of citrate
anticoagulant (0.11 M sodium citrate /citric acid in PBS, pH 6.5).
The platelet population in these whole blood samples was
identified using flow cytometry. Samples were labelled with
hamster anti-mouse CD61 PE (BD Biosciences) for 10 minutes
at room temperature. The red cell population was lysed using
UtiLyse
TM (Dako Cytomation) and the samples were analyzed on
a FacsCalibur flow cytometer (BD Biosciences) in the logarithmic
mode. The platelet population in the blood samples after lysis of
the red blood cells, was also counted manually using phase
contrast microscopy in a Neubauer chamber.
Animal experiments
All animal studies conducted in this study have been approved
by the ethical committee at Lund University.
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